- Zacks Small Cap Research•last year
On November 11, 2015, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the third quarter of 2015 and provided a business update. This acceptance will enable the company to expand recruitment for the ongoing Phase 2 clinical trial to three planned clinical trial sites in the U.S., including Mount Sinai School of Medicine in New York City.
- Motley Fool•last year
The biotech giant had other options.
- Market Realist•last year
Opko Health (OPK) makes up 1.25% of the SPDR S&P Biotech ETF (XBI). It is a mid-cap stock and has a market cap of ~$6 billion.
Requested symbol wasn't found
NasdaqGS . Currency in USD
Add to watchlist
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|